95-83-0 4-氯邻苯二胺

运输信息：常温运输。危险描述：危险品运输编号2811，危险类别6.1，包装等级I、II、III；危险性类别致癌性类别2、眼部刺激类别2、经皮刺激类别2、特异性靶器官毒性-一次接触类别3；危险标志GHS07、GHS08；危险性描述H315、H319、H335、H351；WGK Germany:3，RTECS号SS8850000，F:8，TSCA listed，海关编码29215900，存储类别11-可燃固体。

用于有机合成，发生环化及环缩合反应形成苯并咪唑；需在低温通风干燥库房储存，与强氧化剂分开存放，灭火剂可选用水、二氧化碳、泡沫、砂土。

化学合成; 医药中间体

合成路线 1（2-硝基-5-氯苯胺为原料）

• 步骤：向含有卤化硝基芳烃（1mmol）、5% Pd/C催化剂和甲醇（5mL）的混合溶液中，加入水合肼（10mmol）。将反应混合物在80℃下回流加热5分钟。反应完成后，将混合物过滤以移除催化剂，随后在真空条件下浓缩滤液。粗产物通过快速柱色谱法进行纯化。
• 产率：93%
• 参考文献：[1] Journal of Organic Chemistry, 2013, vol. 78, #9, p. 4530-4542；[2] Synlett, 2014, vol. 25, #10, p. 1403-1408；[3] Journal of Medicinal Chemistry, 1995, vol. 38, #22, p. 4367-4379；[4] Journal of Organic Chemistry, 1995, vol. 60, #18, p. 5838-5842；[5] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, #2, p. 187-190

合成路线 2（2-硝基-5-氯苯胺为原料）

• 步骤：将5.0mg Pd-gCN（5.0wt％Pd）催化剂加入到1.0mM硝基芳烃在乙醇（2mL）和2mM（1.2当量0.07mL）60％的水合肼溶液中。将混合物在回流温度（70℃）下放入10mL圆底烧瓶中4小时，然后在室温下冷却。过滤所得物质，滤液经硅胶柱层析，得到相应的产物。对于二硝基芳烃底物，使用4.0mM（2.4当量0.14mL）60％的水合肼溶液。
• 产率：92%
• 参考文献：[1] Journal of Organic Chemistry, 2001, vol. 66, #3, p. 919-924；[2] Journal of Organic Chemistry, 2013, vol. 78, #9, p. 4530-4542；[3] Applied Organometallic Chemistry, 2015, vol. 29, #4, p. 187-194；[4] Chemistry - A European Journal, 2018, vol. 24, #36, p. 8989-8993；[5] Applied Catalysis A: General, 2016, vol. 523, p. 31-38；[6] Applied Organometallic Chemistry, 2017, vol. 31, #12；[7] Catalysis Communications, 2017, vol. 99, p. 57-60；[8] Catalysis Letters, 2014, vol. 144, #3, p. 439-446；[9] Catalysis Science and Technology, 2015, vol. 5, #1, p. 286-295；[10] Applied Organometallic Chemistry, 2018, vol. 32, #1；[11] Tetrahedron Letters, 1994, vol. 35, #23, p. 3965-3966；[12] Organic Preparations and Procedures International, 2000, vol. 32, #5, p. 485-488；[13] Tetrahedron, 2017, vol. 73, #27-28, p. 3898-3904；[14] Molecules, 2018, vol. 23, #12；[15] Chemische Berichte, 1958, vol. 91, p. 2557,2560；[16] Chemische Berichte, 1903, vol. 36, p. 4032；[17] Journal of the Chemical Society, 1945, p. 694,697；[18] Anilinokr.Promysl.3<1933>391,401；[19] Chem.Abstr., 1934, p. 1670,1671；[20] Yuki Gosei Kagaku Kyokaishi, 1955, vol. 13, p. 413,415；[21] Chem.Abstr., 1957, p. 2747；[22] Bulletin of the Chemical Society of Japan, 1954, vol. 27, p. 602,603；[23] Zhurnal Obshchei Khimii, 1949, vol. 19, p. 1545,1550；[24] J. Gen. Chem. USSR (Engl. Transl.), 1949, vol. 19, p. 1555；[25] Journal of Medicinal Chemistry, 1981, vol. 24, #1, p. 93-101；[26] Journal of the Indian Chemical Society, 1983, vol. 60, #11, p. 1077-1079；[27] Bioorganic and Medicinal Chemistry, 1998, vol. 6, #2, p. 163-172；[28] Magnetic Resonance in Chemistry, 1998, vol. 36, #7, p. 529-532；[29] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, #2, p. 187-190；[30] Russian Journal of General Chemistry, 2004, vol. 74, #3, p. 428-437；[31] Patent: US6194447, 2001, B1；[32] European Journal of Medicinal Chemistry, 2009, vol. 44, #4, p. 1794-1800；[33] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, #1, p. 398-404；[34] Journal of the Serbian Chemical Society, 2014, vol. 79, #3, p. 277-282；[35] Molecules, 2014, vol. 19, #7, p. 9736-9759；[36] RSC Advances, 2015, vol. 5, #63, p. 51347-51363；[37] ChemCatChem, 2016, vol. 8, #8, p. 1485-1489；[38] Catalysis Communications, 2016, vol. 84, p. 25-29；[39] RSC Advances, 2016, vol. 6, #94, p. 91275-91294；[40] Patent: CN106220633, 2016, A. Location in patent: Paragraph 0016; 0028；[41] Green Chemistry, 2017, vol. 19, #3, p. 809-815；[42] ChemCatChem, 2017, vol. 9, #19, p. 3743-3751；[43] Patent: CN106336415, 2017, A. Location in patent: Paragraph 0026；[44] European Journal of Organic Chemistry, 2018, vol. 2018, #2, p. 209-214；[45] Patent: CN108329278, 2018, A. Location in patent: Paragraph 0011-0012; 0017-0018; 0023-0024